The present study evaluates correlation of renin-angiotensin system (RAS) polymorphisms with the level of panel-reactive antibodies (PRA) in renal transplant recipients. 108 renal transplant recipients including 42 (38.9%) females and 66 (61.1%) males were enrolled to the study. The current patients’ sera were screened by standard complement-dependent microlymphocytotoxicity technique. RAS polymorphisms composed of angiotensin-converting enzyme (ACE I/D), angiotensinogene (AGT M235T), and angiotensin II receptor type 1 (ATR1 A1166C) were determined by polymerase chain reaction. PRA<10, 10-29, 30-49, and >=50 considered as negative, mild, moderate, and severe positive PRA, respectively. Statistical analysis was done by SPSS for windows 11.0. Values were expressed as mean±SD; P<0.05 was considered significance. Twelve (11.1%) patients had positive PRA, among of them 10 (83.3%) had mild and 2 (16.7%) of them had moderate PRA levels, we had not sever positive PRA. Ninety-six of cases (88.9%) were negative for PRA. There was no significant relationship with PRA and parameters including of age, gender, hemodialysis longevity, history of blood transfusion, causes of ESRD, pregnancy and blood groups (P>0.05). The frequencies of RAS polymorphisms were: 31.5% DD and 64.8% non-DD genotype for angiotensin-converting enzyme (ACE); 27.8% TT and 68.5% non-TT genotype for angiotensinogen (AGT); 5.6% CC and 90.7% non-CC for angiotensin receptor type 1 (ATR1). There was no significant correlation between discrete RAS polymorphisms (alone or together) and the degree of panel antibody reactivity (P>0.05). We suggest that none of the RAS polymorphisms could predict the positivity degree of PRA level.